Enliven Therapeutics (ELVN) Price & Analysis

Compare

305 Followers

ELVN Stock Chart & Stats

$21.40

$0.01(0.04%)

At close: Jan 08 4:00 PM EST

$21.40

$0.01(0.04%)

Day’s Range― - ―

52-Week Range$13.30 - $25.96

Previous CloseN/A

Volume37.78K

Average Volume (3M)566.65K

Market Cap

$1.22B

Enterprise Value$793.88M

Total Cash (Recent Filing)$477.56M

Total Debt (Recent Filing)$387.00K

Price to Earnings (P/E)―

Beta1.19

Next Earnings

Mar 12, 2026

EPS Estimate

-0.38

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.32

Shares Outstanding59,347,317

10 Day Avg. Volume450,285

30 Day Avg. Volume566,652

Financial Highlights & Ratios

PEG Ratio1.99

Price to Book (P/B)3.42

Price to Sales (P/S)0.00

P/FCF Ratio-14.46

Enterprise Value/Market Cap0.65

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-7.42

Forecast

1Y Price Target

$39.50

Price Target Upside84.58% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

EPS Forecast (FY)-1.93

Revenue Forecast (FY)$7.14K

Bulls Say, Bears Say

Bulls Say

Clinical Trials And DevelopmentEnliven remains on track to launch an initial Phase III pivotal trial for ELVN-001 in CML in 2026.

Efficacy And SafetyELVN-001 has demonstrated an attractive safety profile with a low incidence of adverse events and dose reductions.

Financial PositionEnliven ended the period with $477.6M in cash, cash equivalents, and marketable securities, which is expected to provide runway into the first half of 2029.

Bears Say

Competitive PressureTerns will likely initiate a Phase 3 trial with '701 in 2026 which would slow the enrollment speed of Enliven's pivotal trial.

Market SentimentShort interest in the stock is relatively high at 18.6% of the float.

Trial Design UncertaintyEnliven has yet to decide on the Phase 3 trial design.

Enliven Therapeutics News

Enliven reports Q3 EPS (32c) vs. (48c) last year

As of September 30, the company had cash, cash equivalents and marketable securities totaling $477.6M, expected to provide...

24d ago

ELVN

Enliven Therapeutics: Strategic Advancements and Promising Clinical Progress Support Buy Rating

JonesTrading analyst Soumit Roy has maintained their bullish stance on ELVN stock, giving a Buy rating today. Soumit...

22d ago

ELVN

Enliven Therapeutics: Promising Financial Discipline and Strategic Positioning Justify Buy Rating

Enliven Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Robert Burns from...

22d ago

ELVN

Enliven Therapeutics Reports Q3 2025 Financial Results

Enliven Therapeutics, Inc. ( ($ELVN) ) has released its Q3 earnings. Here is a breakdown of the information...

23d ago

ELVN

Promising Future for Enliven Therapeutics: Buy Rating Backed by Strong Phase 1 Data and Financial Stability

Enliven Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sam Slutsky from...

24d ago

ELVN

Enliven Therapeutics: Strategic Positioning and Promising Data Justify Buy Rating

JonesTrading analyst Soumit Roy has maintained their bullish stance on ELVN stock, giving a Buy rating yesterday. Soumit...

1M ago

ELVN

Promising Investment Opportunity: Enliven Therapeutics’ ELVN-001 Shows Strong Potential in CML Treatment

Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on Enliven Therapeutics and keeping the price target...

1M ago

ELVN

Enliven being 20% down on Terns news ‘makes no sense,’ says Mizuho

Mizuho analyst Salim Syed notes that Terns Pharmaceuticals’ (TERN) TERN-701’s ASH abstract was released and while “there is...

1M ago

ELVN

TERN

Enliven Therapeutics Advances in CML Treatment with ELVN-001 Study

Enliven Therapeutics, Inc. (($ELVN)) announced an update on their ongoing clinical study. Study Overview: Enliven Therapeutics, Inc. is...

1M ago

ELVN

Enliven Therapeutics’ ELVN-001: A Promising Phase 1 Study for Chronic Myeloid Leukemia

Enliven Therapeutics, Inc. (($ELVN)) announced an update on their ongoing clinical study. Enliven Therapeutics, Inc. is conducting a...

1M ago

ELVN

Enliven, Novartis drugs poised to lead in CML markets, says Clear Street

After Novartis (NVS) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency...

2M ago

NVS

ELVN

Enliven Therapeutics: Strong Buy Rating Backed by Promising Clinical Results and Robust Financial Position

JonesTrading analyst Soumit Roy has maintained their bullish stance on ELVN stock, giving a Buy rating today. Soumit...

4M ago

ELVN

Enliven Therapeutics: Strong Financial Foundation and Promising ELVN-001 Development Justify Buy Rating

In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Enliven Therapeutics, with...

4M ago

ELVN

Enliven files automatic mixed securities shelf

17:01 EDT Enliven (ELVN) files automatic mixed securities shelf Published first on TheFly – the ultimate source for...

4M ago

ELVN

ELVN FAQ

What was Enliven Therapeutics’s price range in the past 12 months?

Enliven Therapeutics lowest stock price was $13.30 and its highest was $25.96 in the past 12 months.

What is Enliven Therapeutics’s market cap?

Enliven Therapeutics’s market cap is $1.22B.

When is Enliven Therapeutics’s upcoming earnings report date?

Enliven Therapeutics’s upcoming earnings report date is Mar 12, 2026 which is in 96 days.

How were Enliven Therapeutics’s earnings last quarter?

Enliven Therapeutics released its earnings results on Nov 12, 2025. The company reported -$0.32 earnings per share for the quarter, beating the consensus estimate of -$0.433 by $0.113.

Is Enliven Therapeutics overvalued?

According to Wall Street analysts Enliven Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Enliven Therapeutics pay dividends?

Enliven Therapeutics does not currently pay dividends.

What is Enliven Therapeutics’s EPS estimate?

Enliven Therapeutics’s EPS estimate is -0.38.

How many shares outstanding does Enliven Therapeutics have?

Enliven Therapeutics has 59,347,317 shares outstanding.

What happened to Enliven Therapeutics’s price movement after its last earnings report?

Enliven Therapeutics reported an EPS of -$0.32 in its last earnings report, beating expectations of -$0.433. Following the earnings report the stock price went down -0.148%.

Which hedge fund is a major shareholder of Enliven Therapeutics?

Currently, no hedge funds are holding shares in ELVN

Enliven Therapeutics Stock Smart Score

Underperform

Fundamentals

Return on Equity

-25.43%

Trailing 12-Months

Asset Growth

60.72%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Enliven Therapeutics

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.

Enliven Therapeutics (ELVN) Earnings & Revenues

Historic Earnings Reports

ELVN Stock 12 Month Forecast

Average Price Target

$39.50

▲(84.58% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"17":"$17","25":"$25","33":"$33","41":"$41","49":"$49"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":48,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$48.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":39.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$39.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$35.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[17,25,33,41,49],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.42,25.310769230769232,27.201538461538462,29.092307692307692,30.983076923076922,32.87384615384615,34.76461538461538,36.65538461538462,38.54615384615384,40.43692307692308,42.3276923076923,44.21846153846154,46.10923076923077,{"y":48,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.42,24.65692307692308,25.893846153846155,27.130769230769232,28.36769230769231,29.604615384615386,30.841538461538462,32.07846153846154,33.315384615384616,34.55230769230769,35.78923076923077,37.026153846153846,38.26307692307692,{"y":39.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.42,24.310769230769232,25.201538461538462,26.092307692307692,26.983076923076926,27.873846153846156,28.764615384615386,29.655384615384616,30.546153846153846,31.43692307692308,32.32769230769231,33.21846153846154,34.10923076923077,{"y":35,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":27.63,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.43,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.5,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.86,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.83,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.88,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.85,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.14,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.65,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.73,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.89,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.82,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.42,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >